TY - JOUR AU - Goodarzi, Elham AU - Beiranvand, Reza AU - Mosavi-Jarrahi, Alireza AU - Naemi, Hasan AU - Khazaei, Zaher PY - 2019/12/26 Y2 - 2024/03/29 TI - Epidemiology Incidence and Mortality Worldwide Common cancers in males and Their Relationship with the Human Development Index (HDI): An Ecological Study Updated in the World: Incidence and Mortality Worldwide Common cancers in males and Human Development Index (HDI) JF - Journal of Contemporary Medical Sciences JA - J. Contemp. Med. Sci. VL - 5 IS - 6 SE - Articles DO - 10.22317/jcms.v5i6.664 UR - https://jocms.org/index.php/jcms/article/view/664 SP - 281-303 AB - <p>This article provides a status report on the global burden of common cancers in male in worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality.&nbsp;</p><p>Based on the results of cancer records in 2018, 9456418 cases of malignancy were recorded in males, with cancer (1368524 cases, 14.5 %), prostat cancer (1276106 cases, 13.5%), colorectal cancer(1026215 cases, 10.9%), stomach cancer(683754 cases, 7.2%) and liver cancer (596574 caces, 6.3%) were the five most common&nbsp; cancers in men worledwide. the total of deaths due to cancer in human in 2018 is 5385640. the five cases of death due to cancer in men worldwide are lung cancer (1184947 case, 22%), liver (548375 cases, 2.10%), stumach cancer (513555 cases, 9.5%), colorectal cancer (484224 case, 9%) and prostat cancer (358989 cases, 7.7 %). our resulth showed that there was a positive correlation between the incidence of lung cancer ( r= 0.629, p&lt;0.0001), prostat cancer (r= 0.534, p&lt;0.0001), colorectal cancer (r=0.745, p&lt;0.0001) and stomach cancer (r=0.268, p&lt;0.0001) with HDI index, while there was no significant relationship between liver cancer and the HDI (r=0.079, p&gt;0.05).&nbsp;</p><p>the results also showed that there was a positive and significant correlation between mortality from lung cancer (r=0.632, p&lt;0.0001) and colorectal (r=0.627, p&lt;0.0001) with HDI, wereas&nbsp; this correlation was negative for prostate cancer (r=-0.187, p&lt;0.05).</p> ER -